WO1999007839A3 - Immunoprotective influenza antigen and its use in vaccination - Google Patents
Immunoprotective influenza antigen and its use in vaccination Download PDFInfo
- Publication number
- WO1999007839A3 WO1999007839A3 PCT/EP1998/005106 EP9805106W WO9907839A3 WO 1999007839 A3 WO1999007839 A3 WO 1999007839A3 EP 9805106 W EP9805106 W EP 9805106W WO 9907839 A3 WO9907839 A3 WO 9907839A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antigen
- influenza
- immunoprotective
- vaccination
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69832706T DE69832706T2 (en) | 1997-08-05 | 1998-08-05 | IMMUNO-PROTECTING INFLUENZAANTIGEN AND ITS USE FOR VACCINATION |
EP98946321A EP0996717B1 (en) | 1997-08-05 | 1998-08-05 | Immunoprotective influenza antigen and its use in vaccination |
AU93416/98A AU745951B2 (en) | 1997-08-05 | 1998-08-05 | New immunoprotective influenza antigen and its use in vaccination |
CA2297786A CA2297786C (en) | 1997-08-05 | 1998-08-05 | New immunoprotective influenza antigen and its use in vaccination |
JP2000506324A JP5132851B2 (en) | 1997-08-05 | 1998-08-05 | New immunoprotective influenza antigens and their use in vaccination |
AT98946321T ATE312172T1 (en) | 1997-08-05 | 1998-08-05 | IMMUNOPROTECTIVE INFLUENCY ANTIGEN AND ITS USE FOR VACCINATION |
US11/374,922 US7732130B2 (en) | 1997-08-05 | 2006-03-14 | Immunoprotective influenza antigen and its use in vaccination |
US12/795,506 US7993652B2 (en) | 1997-08-05 | 2010-06-07 | Immunoprotective influenza antigen and its use in vaccination |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97202434.3 | 1997-08-05 | ||
EP97202434 | 1997-08-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999007839A2 WO1999007839A2 (en) | 1999-02-18 |
WO1999007839A3 true WO1999007839A3 (en) | 1999-05-14 |
Family
ID=8228624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/005106 WO1999007839A2 (en) | 1997-08-05 | 1998-08-05 | Immunoprotective influenza antigen and its use in vaccination |
Country Status (10)
Country | Link |
---|---|
US (1) | US7732130B2 (en) |
EP (1) | EP0996717B1 (en) |
JP (2) | JP5132851B2 (en) |
AT (1) | ATE312172T1 (en) |
AU (1) | AU745951B2 (en) |
CA (1) | CA2297786C (en) |
DE (1) | DE69832706T2 (en) |
DK (1) | DK0996717T3 (en) |
ES (1) | ES2255181T3 (en) |
WO (1) | WO1999007839A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8945579B2 (en) | 2006-03-07 | 2015-02-03 | Vaxinnate Corporation | Methods of treatment with compositions that include hemagglutinin |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7731972B1 (en) | 2000-02-04 | 2010-06-08 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Immunoprotective influenza antigen and its use in vaccination |
JP5132851B2 (en) | 1997-08-05 | 2013-01-30 | フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー(ヴェーイーベー・ヴェーゼットウェー) | New immunoprotective influenza antigens and their use in vaccination |
ATE412434T1 (en) | 1998-11-30 | 2008-11-15 | Cytos Biotechnology Ag | MOLECULAR ARRANGEMENT OF ALLERGENS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE |
GB0008582D0 (en) * | 2000-04-08 | 2000-05-31 | Adprotech Plc | DNA immunization vectors |
EP1276852B1 (en) * | 2000-04-14 | 2010-11-17 | Wisconsin Alumni Research Foundation | Viruses comprising mutated ion channel protein |
AU2001252390A1 (en) * | 2000-05-01 | 2001-11-12 | Powderject Vaccines, Inc. | Nucleic acid immunization |
AU2001252458A1 (en) | 2000-05-05 | 2001-11-20 | Martin Bachmann | Molecular antigen arrays and vaccines |
GB0025229D0 (en) * | 2000-10-14 | 2000-11-29 | Adprotech Ltd | Veterinary immunisation vectors |
US7094409B2 (en) | 2001-01-19 | 2006-08-22 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
US7128911B2 (en) | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
US7264810B2 (en) * | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
US7361352B2 (en) | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
ES2335979T3 (en) | 2001-09-14 | 2010-04-07 | Cytos Biotechnology Ag | IMMUNOSTIMULATOR CPG PACKAGING IN VIRUS SIMILAR PARTICLES: PREPARATION METHOD AND ITS USE. |
US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
US7351413B2 (en) | 2002-02-21 | 2008-04-01 | Lorantis, Limited | Stabilized HBc chimer particles as immunogens for chronic hepatitis |
GB0204154D0 (en) * | 2002-02-22 | 2002-04-10 | Adprotech Ltd | Cat immunisation vectors |
CN1652815A (en) * | 2002-03-13 | 2005-08-10 | 麒麟麦酒株式会社 | Human monoclonal antibodies to influenza M2 protein and methods of making and using same |
BR0312935A (en) | 2002-07-17 | 2005-06-21 | Cytos Biotechnology Ag | Virus-like particle, mutein, vectors for producing said particle and recombinant protein, composition, process for producing antigen repeat and order row, nucleic acid molecule, host cell, method for producing said particle and use of vaccine composition |
RU2326693C2 (en) | 2002-07-18 | 2008-06-20 | Цитос Байотекнолоджи Аг | Hapten-carrier conjugates and application |
MXPA05000819A (en) | 2002-07-19 | 2005-08-29 | Cytos Biotechnology Ag | Vaccine compositions containing amyloid beta1-6 antigen arrays. |
CA2522081C (en) * | 2003-04-23 | 2013-01-29 | Wisconsin Alumni Research Foundation | Recombinant influenza viruses holding a mutation in a transmembrane protein gene |
BRPI0411854A (en) * | 2003-06-23 | 2006-08-29 | Baxter Int | protein vehicles for vaccines |
KR20070086344A (en) | 2004-11-19 | 2007-08-27 | 위스콘신 얼럼나이 리서어치 화운데이션 | Recombinant influenza vectors with tandem transcription units |
EP2295465B1 (en) | 2004-12-06 | 2013-02-13 | Kyowa Hakko Kirin Co., Ltd. | Human monoclonal antibodies to influenza M2 protein and methods of making and using same |
US20090162400A1 (en) * | 2004-12-21 | 2009-06-25 | Powell Thomas J | Compositions of influenza viral proteins and methods of use thereof |
JP2009514536A (en) * | 2005-11-07 | 2009-04-09 | シドニー キンメル キャンサー センター | CD40 ligand fusion protein vaccine |
CA2632483C (en) | 2005-12-06 | 2014-11-25 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Improved influenza vaccine |
CA2647985C (en) | 2006-03-31 | 2014-12-30 | Warf-Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
JP2009543554A (en) | 2006-07-14 | 2009-12-10 | サノフィ パスツール バイオロジクス カンパニー | Construction of recombinant viral vaccines by direct transposon-mediated insertion of foreign immune determinants into vector viral proteins |
JP2010504760A (en) | 2006-09-29 | 2010-02-18 | サノフィ パスツール バイオロジクス カンパニー | Recombinant rhinovirus vector |
DK2069503T3 (en) * | 2006-11-15 | 2016-02-15 | Folia Biotech Inc | PAPAYAMOSAIKVIRUS-BASED VACCINES AGAINST INFLUENZA |
WO2008156778A2 (en) | 2007-06-18 | 2008-12-24 | Tokiko Watanabe | Influenza m2 protein mutant viruses as live influenza attenuated vaccines |
WO2009016639A2 (en) | 2007-08-02 | 2009-02-05 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope influenza vaccines |
MX2010005229A (en) | 2007-11-12 | 2010-11-05 | Univ Pennsylvania | Novel vaccines against multiple subtypes of influenza virus. |
EP2280991B1 (en) | 2008-04-18 | 2016-06-22 | VaxInnate Corporation | Deletion mutants of flagellin and methods of use |
US20110206727A1 (en) * | 2008-07-30 | 2011-08-25 | Denis Leclerc | Multivalent Vaccines Based on Papaya Mosaic Virus and Uses Thereof |
EP2168987A1 (en) * | 2008-09-22 | 2010-03-31 | Mucosis B.V. | Multifunctional linker protein containing an antibody against hemagglutinin, a conserved influenza antigen and an immunostimulating carrier binding domain |
KR20120052369A (en) | 2009-07-31 | 2012-05-23 | 팍스박스, 인코포레이티드 | Adenoviral-based vectors |
US8883165B2 (en) | 2009-08-28 | 2014-11-11 | The Chemo-Sero-Therapeutic Research Institute | Modified peptide vaccine derived from influenza M2 |
WO2011046925A1 (en) * | 2009-10-12 | 2011-04-21 | Technovax, Inc. | Respiratory syncytial virus (rsv) virus-like particles (vlps) |
JP2013507990A (en) | 2009-10-26 | 2013-03-07 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | High-titer recombinant influenza virus with enhanced replication in Vero cells |
WO2011054995A2 (en) | 2009-11-06 | 2011-05-12 | Chimera Pharma, S. L. U. | PROPHYLACTIC FLU VACCINES FROM VIRAL CAPSIDS OF BIRNAVIRUS CONTAINING THE M2e ANTIGEN OF THE FLU VIRUS |
US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
US9303070B2 (en) | 2011-02-22 | 2016-04-05 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines |
US8932598B2 (en) | 2012-08-28 | 2015-01-13 | Vaxinnate Corporation | Fusion proteins and methods of use |
AU2014290203B2 (en) | 2013-07-15 | 2020-12-24 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs |
WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
EP3103474A1 (en) * | 2015-06-12 | 2016-12-14 | Institut Pasteur | Live recombinant measles-m2 virus and its use in eliciting immunity against influenza viruses |
WO2017007839A1 (en) | 2015-07-06 | 2017-01-12 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
EP3417056A1 (en) | 2016-02-19 | 2018-12-26 | Wisconsin Alumni Research Foundation (WARF) | Improved influenza b virus replication for vaccine development |
US11241492B2 (en) | 2019-01-23 | 2022-02-08 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to genes in influenza viruses |
WO2020163804A1 (en) | 2019-02-08 | 2020-08-13 | Wisconsin Alumni Research Foundation (Warf) | Humanized cell line |
CN114929269A (en) | 2019-05-01 | 2022-08-19 | 威斯康星校友研究基金会(Warf) | Improved influenza virus replication for vaccine development |
WO2021041624A2 (en) | 2019-08-27 | 2021-03-04 | Yoshihiro Kawaoka | Recombinant influenza viruses with stabilized ha for replication in eggs |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4927390A (en) * | 1987-02-10 | 1990-08-09 | Wellcome Foundation Limited, The | Fusion proteins |
WO1992022575A1 (en) * | 1991-06-19 | 1992-12-23 | Sri International | M-protein peptides of influenza virus as antiviral agents |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3919044A (en) | 1973-03-28 | 1975-11-11 | Armour Pharma | Processes for concentrating and purifying viruses and viral antigens |
FR2695563B1 (en) | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticles carrying antigens and their use for the induction of humoral or cellular responses. |
US5759551A (en) | 1993-04-27 | 1998-06-02 | United Biomedical, Inc. | Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines |
DK0708656T3 (en) * | 1993-04-27 | 2002-12-02 | United Biomedical Inc | Antigenic LHRH peptide constructs and universal synthetic immune stimulators for vaccines |
EP0712442B1 (en) * | 1993-07-30 | 2002-03-27 | Medeva Holdings B.V. | Vaccine compositions |
US5691189A (en) * | 1994-01-19 | 1997-11-25 | Bristol-Myers Squibb Company | Saccharomyces cerevisiae expressing M2 protein of influenza A virus |
GB9424631D0 (en) * | 1994-12-06 | 1995-01-25 | Lynxvale Ltd | Modulating the immune response |
GB9521568D0 (en) * | 1995-10-20 | 1995-12-20 | Lynxvale Ltd | Delivery of biologically active polypeptides |
EP0941315B1 (en) | 1996-11-26 | 2006-03-01 | Stressgen Biotechnologies Corporation | Fusion proteins containing stress proteins for inducing immune responses |
JP5132851B2 (en) | 1997-08-05 | 2013-01-30 | フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー(ヴェーイーベー・ヴェーゼットウェー) | New immunoprotective influenza antigens and their use in vaccination |
US6169175B1 (en) | 1997-08-06 | 2001-01-02 | Centers For Disease Control And Prevention | Preparation and use of recombinant influenza A virus M2 construct vaccines |
US20020015951A1 (en) | 2000-01-06 | 2002-02-07 | Bader Joel S. | Method of analyzing a nucleic acid |
-
1998
- 1998-08-05 JP JP2000506324A patent/JP5132851B2/en not_active Expired - Lifetime
- 1998-08-05 ES ES98946321T patent/ES2255181T3/en not_active Expired - Lifetime
- 1998-08-05 EP EP98946321A patent/EP0996717B1/en not_active Revoked
- 1998-08-05 DK DK98946321T patent/DK0996717T3/en active
- 1998-08-05 CA CA2297786A patent/CA2297786C/en not_active Expired - Lifetime
- 1998-08-05 DE DE69832706T patent/DE69832706T2/en not_active Expired - Lifetime
- 1998-08-05 AT AT98946321T patent/ATE312172T1/en active
- 1998-08-05 WO PCT/EP1998/005106 patent/WO1999007839A2/en active IP Right Grant
- 1998-08-05 AU AU93416/98A patent/AU745951B2/en not_active Expired
-
2006
- 2006-03-14 US US11/374,922 patent/US7732130B2/en active Active
-
2009
- 2009-10-16 JP JP2009239092A patent/JP2010059164A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4927390A (en) * | 1987-02-10 | 1990-08-09 | Wellcome Foundation Limited, The | Fusion proteins |
WO1992022575A1 (en) * | 1991-06-19 | 1992-12-23 | Sri International | M-protein peptides of influenza virus as antiviral agents |
Non-Patent Citations (3)
Title |
---|
M. SANSOM ET AL.: "Influenza virus M2 protein: a molecular modelling study of the ion channel.", PROTEIN ENGINEERING, vol. 6, no. 1, January 1993 (1993-01-01), OXFORD, GB, pages 65 - 74, XP000335249 * |
M. TOSTESON ET AL.: "Reconstitution of the influenza virus M2 ion channel in lipid bilayers.", JOURNAL OF MEMBRANE BIOLOGY, vol. 142, no. 1, 1994, NEW YORK, NY, USA, pages 117 - 126, XP002054196 * |
P. POUWELS ET AL.: "The potential of Lactobacillus as a carrier for oral immunization: Development and preliminary characterization of vector systems for targeted delivery of antigens.", JOURNAL OF BIOTECHNOLOGY, vol. 44, no. 1-3, 26 January 1996 (1996-01-26), AMSTERDAM, NL, pages 183 - 192, XP000572655 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8945579B2 (en) | 2006-03-07 | 2015-02-03 | Vaxinnate Corporation | Methods of treatment with compositions that include hemagglutinin |
US9200042B2 (en) | 2006-03-07 | 2015-12-01 | Vaxinnate Corporation | Flagellin fusion proteins |
Also Published As
Publication number | Publication date |
---|---|
US20060246092A1 (en) | 2006-11-02 |
EP0996717A2 (en) | 2000-05-03 |
DE69832706D1 (en) | 2006-01-12 |
ATE312172T1 (en) | 2005-12-15 |
JP2001512748A (en) | 2001-08-28 |
WO1999007839A2 (en) | 1999-02-18 |
CA2297786C (en) | 2011-06-14 |
AU9341698A (en) | 1999-03-01 |
EP0996717B1 (en) | 2005-12-07 |
ES2255181T3 (en) | 2006-06-16 |
JP2010059164A (en) | 2010-03-18 |
DE69832706T2 (en) | 2006-08-10 |
CA2297786A1 (en) | 1999-02-18 |
AU745951B2 (en) | 2002-04-11 |
JP5132851B2 (en) | 2013-01-30 |
DK0996717T3 (en) | 2006-04-10 |
US7732130B2 (en) | 2010-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999007839A3 (en) | Immunoprotective influenza antigen and its use in vaccination | |
EP1347055A3 (en) | Compounds for immunotherapy and diagnosis of tuberculosis | |
WO1999042076A3 (en) | Compounds and methods for immunotherapy and diagnosis of tuberculosis | |
WO1999041369A3 (en) | Genetic vaccine vector engineering | |
WO1998016646A3 (en) | Compounds and methods for immunotherapy and diagnosis of tuberculosis | |
WO1999057280A3 (en) | Neisseria meningitidis antigens and compositions | |
WO1998053075A3 (en) | Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use | |
WO2003011115A3 (en) | Peptide-based multimeric targeted contrast agents | |
WO2002079232A3 (en) | Reducing the immunogenicity of fusion proteins | |
BRPI0113477B8 (en) | fusion protein for delivering a peptide, protein, glycoprotein or oligonucleotide into a cell | |
WO2002018572A3 (en) | Membrane penetrating peptides and uses thereof | |
DK1032374T3 (en) | Sphroids, Methods and Pharmaceutical Preparations | |
WO1998013500A3 (en) | Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines | |
WO2003072746A3 (en) | Subtilisin carlsberg proteins with reduced immunogenicity | |
WO2003089574A3 (en) | Synthetic glyco-lipo-peptides as vaccines | |
WO2002024739A3 (en) | Spas-1 cancer antigen | |
WO2003011331A3 (en) | Materials and methods relating to improved vaccination strategies | |
WO2005035779A3 (en) | Method | |
ATE346931T1 (en) | CLOSTRIDIUM PERFRINGENS VACCINE | |
WO2001074845A3 (en) | Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof | |
WO2002083713A3 (en) | Echinocandin process | |
WO1997011669A3 (en) | MHC-class II restricted melanoma antigens and their use in therapeutic methods | |
WO2001088137A3 (en) | Human myd88 adapter-like protein and functional fragments thereof | |
EP1731611A3 (en) | Eimeria hydrophilic polypeptides as vaccines | |
WO2004003009A3 (en) | Francisella tularensis immunogenic proteins and dna encoding these |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 93416/98 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2297786 Country of ref document: CA Ref country code: CA Ref document number: 2297786 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998946321 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998946321 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 93416/98 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998946321 Country of ref document: EP |